Episode
Amplia Therapeutics Leadership Shift | Sydney News
- Published
- Jun 30, 2026
- Duration seconds
- 135
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/sydney-news-today-2-min-news-the-daily-news-now-7568669/episodes/amplia-therapeutics-leadership-shift-sydney-news/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/sydney-news-today-2-min-news-the-daily-news-now-7568669/amplia-therapeutics-leadership-shift-sydney-news.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Amplia Therapeutics is shaking up its leadership with Jane Bell AM stepping in as chairman, timed perfectly with breakthrough clinical data for its drug narmafotinib — showing a 36% response rate and over 11 months median survival in advanced pancreatic cancer patients, without added toxicity. Backed by recent Nature Medicine research validating its FAK-targeting approach, the company is poised for FDA discussions, fast-track and orphan drug designations, and scaling manufacturing — all while exploring applications in ovarian cancer, pulmonary fibrosis, and as a companion therapy for KRAS inhibitors. This isn’t just a boardroom change — it’s the launchpad for turning science into market reality. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/5a2e5d65e4cff479